Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GMNN | O75496 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | STAT6 | P42226 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | PYGL | P06737 | 7/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9234118 | 1.00 | KDM4E (0.45) | KDM4EGMNNLMNAMAPTBLM | |
| SCHEMBL2516886 | 0.82 | KDM4E (0.45) | KDM4EGMNNLMNAMAPTBLM | |
| SCHEMBL8663242 | 0.79 | HIF1A (0.46) | KDM4EGMNNLMNAMAPTBLM | |
| SCHEMBL2524005 | 0.78 | KDM4E (0.46) | KDM4EGMNNLMNAMAPTBLM | |
| SCHEMBL5079246 | 0.75 | KDM4E (0.46) | KDM4EGMNNLMNAMAPTBLM | |
| SCHEMBL4361970 | 0.75 | KDM4E (0.46) | KDM4EGMNNLMNAMAPTBLM | |
| SCHEMBL8465320 | 0.75 | SMN1; SMN2 (0.46) | KDM4EGMNNLMNAMAPTBLM | |
| SCHEMBL8465125 | 0.75 | SMN1; SMN2 (0.46) | KDM4EGMNNLMNAMAPTBLM | |
| SCHEMBL11281347 | 0.75 | KDM4E (0.46) | KDM4EGMNNLMNAMAPTBLM | |
| SCHEMBL8662315 | 0.74 | PYGL (0.43) | KDM4EGMNNLMNAMAPTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0636372-B1 | Antiviral, antitumor, antimetastatic, immune system enhancing 7-thia-guanosine derivatives | ICN PHARMACEUTICALS (US) | 1998-12-02 | — | — | EP | claimed |
| EP-0348446-B1 | ANTIVIRAL ANTITUMOR ANTIMETASTATIC IMMUNE SYSTEM ENHANCING NUCLEOSIDES AND NUCLEOTIDES | UNIV BRIGHAM YOUNG (US) | 1995-08-09 | — | — | EP | claimed |
| EP-0636372-A1 | Antiviral, antitumor, antimetastatic, immune system enhancing 7-thia-guanosine derivatives | BRIGHAM YOUNG UNIVERSITY (US) | 1995-02-01 | — | — | EP | claimed |
| US-20100261667-A1 | 3-ß-D-RIBOFURANOSYLTHIAZOLO[4-5-d]PYRIMIDINE NUCLEOSIDES AND USES THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-7745415-B2 | 3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20080255063-A1 | 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIMIDINE NUCLEOSIDES AND USES THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| EP-0636372-B1 | Antiviral, antitumor, antimetastatic, immune system enhancing 7-thia-guanosine derivatives | ICN PHARMACEUTICALS (US) | 1998-12-02 | — | — | EP | disclosed |
| EP-0348446-B1 | ANTIVIRAL ANTITUMOR ANTIMETASTATIC IMMUNE SYSTEM ENHANCING NUCLEOSIDES AND NUCLEOTIDES | UNIV BRIGHAM YOUNG (US) | 1995-08-09 | — | — | EP | disclosed |
| EP-0636372-A1 | Antiviral, antitumor, antimetastatic, immune system enhancing 7-thia-guanosine derivatives | BRIGHAM YOUNG UNIVERSITY (US) | 1995-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255063-A1 | 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIMIDINE NUCLEOSIDES AND USES THEREOF | DPYD, TYMP, DCTD | KDM4E 3196/4885GMNN 879/4885LMNA 3476/4885 |
| US-20100261667-A1 | 3-ß-D-RIBOFURANOSYLTHIAZOLO[4-5-d]PYRIMIDINE NUCLEOSIDES AND USES THEREOF | TYMP, DPYD, NUDT1 | KDM4E 3257/4885GMNN 776/4885LMNA 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.